Obio Technology Shanghai Corp LtdSHG 688238 Stock Report

Obio Technology Shanghai Corp. Ltd. engages in biomedical basic research, gene therapy drug incubation, and clinical grade gene therapy virus vector CDMO service provision. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2022-03-22. The firm is mainly engaged in providing contract research organization (CRO) services such as gene therapy vector development and gene function research for the basic research of gene therapy, as well as contract research and development production organization (CDMO) services such as pharmaceutical research and clinical sample production for the research and development of gene drugs. The firm mainly conducts business in the European and American markets and the domestic market.